ஜய்துச் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜய்துச் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜய்துச் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் இன்க் Today - Breaking & Trending Today

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results


Posted on
8970
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights.
“We are excited with the opportunities ahead of us, including the continued growth of GOCOVRI which is now the first and only medication approved to treat both OFF and dyskinesia motor complications in Parkinson’s disease,” said Neil F. McFarlane, Chief Executive Officer. “Bolstered by the launch of a second indication, GOCOVRI is now approved to treat approximately 400,000 to 500,000 Parkinson’s patients. The significant progress made across the business in 2020 fueled positive momentum into 2021, and we are leveraging this as we continue to successfully execute our long-term g ....

Neilf Mcfarlane , Sarah Mathieson , Peter Vozzo , Zydus Pharmaceuticals United States Inc , Exchange Commission On , Corporate Communications , Drug Administration , Osmotica Pharmaceuticals , Adamas Pharmaceuticals Inc , Adamas Pharmaceuticals , Chief Executive , Royalty Backed Loan , Healthcare Royalty Partners , Zydus Worldwide , Zydus Pharmaceuticals , United States , Prescribing Information , Private Securities Litigation Reform Act , Adama Annual Report , Exchange Commission , Condensed Consolidated Statements , சாரா மதீஸொந் , ஜய்துச் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் இன்க் , பரிமாற்றம் தரகு ஆன் , பெருநிறுவன தகவல்தொடர்புகள் , அட்மாஸ் மருந்துகள் இன்க் ,

Argentum Pharmaceuticals and Bausch Health Settle Patent Dispute Over JUBLIA®


Argentum Pharmaceuticals and Bausch Health Settle Patent Dispute Over JUBLIA®
News provided by
Share this article
Share this article
NEW YORK, Jan. 13, 2021 /PRNewswire/  Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Bausch Health US, LLC and Kaken Pharmaceutical Co., LTD., related to Argentum s inter partes review petition challenging an Orange Book-listed patent for JUBLIA® (efinaconazole) Topical Solution.
Argentum filed its IPR petition against U.S. Patent 7,214,506 (the 506 Patent ) on May 12, 2017. Argentum and Kaken entered into a confidential settlement agreement and filed a joint motion to terminate Argentum s IPR on November 12, 2020, prior to a decision on Argentum s petition by the Patent Trial & Appeal Board. On January 8 ....

Zydus Pharmaceuticals United States Inc , Argentum Pharmaceuticals , Valeant Pharmaceuticals North America , Kaken Pharmaceutical Co , Bausch Health , Orange Book Listed , Patent Trial , Appeal Board , United States , ஜய்துச் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் இன்க் , பாஷ் ஆரோக்கியம் , ஆரஞ்சு நூல் பட்டியலிடப்பட்டுள்ளது , காப்புரிமை சோதனை , முறையீடு பலகை , ஒன்றுபட்டது மாநிலங்களில் ,